DE2508775C2 - 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung - Google Patents
3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische ZusammensetzungInfo
- Publication number
- DE2508775C2 DE2508775C2 DE2508775A DE2508775A DE2508775C2 DE 2508775 C2 DE2508775 C2 DE 2508775C2 DE 2508775 A DE2508775 A DE 2508775A DE 2508775 A DE2508775 A DE 2508775A DE 2508775 C2 DE2508775 C2 DE 2508775C2
- Authority
- DE
- Germany
- Prior art keywords
- oxo
- triene
- amyloxy
- compound
- amyloxyestra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000001195 anabolic effect Effects 0.000 description 6
- -1 triene steroid Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 230000001548 androgenic effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960001124 trientine Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- FZUGQWJSEBEASU-UHFFFAOYSA-N CCCCC.[I] Chemical compound CCCCC.[I] FZUGQWJSEBEASU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7431840A FR2285138A1 (fr) | 1974-09-20 | 1974-09-20 | Nouveau derive steroide trienique, son procede de preparation et son application comme medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2508775A1 DE2508775A1 (de) | 1976-04-08 |
| DE2508775C2 true DE2508775C2 (de) | 1984-04-12 |
Family
ID=9143293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2508775A Expired DE2508775C2 (de) | 1974-09-20 | 1975-02-28 | 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4105761A (en, 2012) |
| JP (1) | JPS5813560B2 (en, 2012) |
| AR (1) | AR203898A1 (en, 2012) |
| AT (1) | AT343296B (en, 2012) |
| BE (1) | BE826077A (en, 2012) |
| CA (1) | CA1027930A (en, 2012) |
| CH (1) | CH595398A5 (en, 2012) |
| DD (1) | DD118872A5 (en, 2012) |
| DE (1) | DE2508775C2 (en, 2012) |
| DK (1) | DK134408B (en, 2012) |
| ES (1) | ES435087A1 (en, 2012) |
| FR (1) | FR2285138A1 (en, 2012) |
| GB (1) | GB1457396A (en, 2012) |
| HU (1) | HU169763B (en, 2012) |
| IE (1) | IE40943B1 (en, 2012) |
| IL (1) | IL46705A (en, 2012) |
| LU (1) | LU71928A1 (en, 2012) |
| NL (1) | NL7502319A (en, 2012) |
| OA (1) | OA04963A (en, 2012) |
| PL (1) | PL94852B1 (en, 2012) |
| SE (1) | SE407410B (en, 2012) |
| SU (1) | SU555857A3 (en, 2012) |
| ZA (1) | ZA751097B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL51468A (en) * | 1976-02-23 | 1981-01-30 | Sparamedica Ag | 17 -hydroxy- -d-homosteroid derivatives,their preparation and pharmaceutical compositions containing them |
| US4297350A (en) * | 1978-10-10 | 1981-10-27 | The Upjohn Company | Male contraceptive steroids and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH488682A (de) * | 1965-07-30 | 1970-04-15 | Ciba Geigy | Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe |
| FR1491586A (fr) * | 1965-07-30 | 1967-08-11 | Ciba Geigy | Procédé de préparation de delta4, 9, 11-triènes de la série du 19-nor-androstane |
| FR5301M (en, 2012) * | 1966-01-21 | 1967-08-16 | ||
| US3629244A (en) * | 1966-01-21 | 1971-12-21 | Roussel Uclaf | 17beta-ethers of delta 4 9 11-gonatrienes and compositions containing them |
| FR6556M (en, 2012) * | 1967-06-20 | 1968-12-23 |
-
1974
- 1974-09-20 FR FR7431840A patent/FR2285138A1/fr active Granted
-
1975
- 1975-02-21 ZA ZA00751097A patent/ZA751097B/xx unknown
- 1975-02-24 JP JP50021992A patent/JPS5813560B2/ja not_active Expired
- 1975-02-24 HU HURO823A patent/HU169763B/hu unknown
- 1975-02-24 OA OA55423A patent/OA04963A/xx unknown
- 1975-02-25 IL IL46705A patent/IL46705A/xx unknown
- 1975-02-26 CH CH240775A patent/CH595398A5/xx not_active IP Right Cessation
- 1975-02-26 DD DD184439A patent/DD118872A5/xx unknown
- 1975-02-26 ES ES435087A patent/ES435087A1/es not_active Expired
- 1975-02-26 CA CA220,956A patent/CA1027930A/en not_active Expired
- 1975-02-26 US US05/553,249 patent/US4105761A/en not_active Expired - Lifetime
- 1975-02-27 LU LU71928A patent/LU71928A1/xx unknown
- 1975-02-27 IE IE421/75A patent/IE40943B1/xx unknown
- 1975-02-27 SE SE7502232A patent/SE407410B/xx not_active IP Right Cessation
- 1975-02-27 GB GB816675A patent/GB1457396A/en not_active Expired
- 1975-02-27 NL NL7502319A patent/NL7502319A/xx not_active Application Discontinuation
- 1975-02-27 PL PL1975178369A patent/PL94852B1/pl unknown
- 1975-02-27 BE BE153827A patent/BE826077A/xx not_active IP Right Cessation
- 1975-02-27 AT AT150775A patent/AT343296B/de not_active IP Right Cessation
- 1975-02-28 DK DK79675AA patent/DK134408B/da not_active IP Right Cessation
- 1975-02-28 AR AR257818A patent/AR203898A1/es active
- 1975-02-28 DE DE2508775A patent/DE2508775C2/de not_active Expired
- 1975-02-28 SU SU2109651A patent/SU555857A3/ru active
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| SU555857A3 (ru) | 1977-04-25 |
| IE40943B1 (en) | 1979-09-12 |
| IE40943L (en) | 1976-03-20 |
| ATA150775A (de) | 1977-09-15 |
| OA04963A (fr) | 1980-10-31 |
| BE826077A (fr) | 1975-08-27 |
| SE407410B (sv) | 1979-03-26 |
| IL46705A (en) | 1978-12-17 |
| JPS5156440A (en, 2012) | 1976-05-18 |
| FR2285138A1 (fr) | 1976-04-16 |
| PL94852B1 (en, 2012) | 1977-09-30 |
| ZA751097B (en) | 1976-01-28 |
| AU7864975A (en) | 1976-09-02 |
| DK134408B (da) | 1976-11-01 |
| SE7502232L (sv) | 1976-03-22 |
| DE2508775A1 (de) | 1976-04-08 |
| LU71928A1 (en, 2012) | 1975-12-09 |
| HU169763B (en, 2012) | 1977-02-28 |
| AT343296B (de) | 1978-05-26 |
| CA1027930A (en) | 1978-03-14 |
| DK79675A (en, 2012) | 1976-03-21 |
| CH595398A5 (en, 2012) | 1978-02-15 |
| DD118872A5 (en, 2012) | 1976-03-20 |
| GB1457396A (en) | 1976-12-01 |
| IL46705A0 (en) | 1975-04-25 |
| JPS5813560B2 (ja) | 1983-03-14 |
| AR203898A1 (es) | 1975-10-31 |
| NL7502319A (nl) | 1976-03-23 |
| FR2285138B1 (en, 2012) | 1978-07-21 |
| ES435087A1 (es) | 1976-12-16 |
| DK134408C (en, 2012) | 1977-04-04 |
| US4105761A (en) | 1978-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2649925A1 (de) | Neue imidazolidine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| DE2534981A1 (de) | Kardiotonische steroidverbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2508775C2 (de) | 3-oxo-17β-n-amyloxyöstra-4,9,11-trien, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zusammensetzung | |
| DE3336292A1 (de) | Neue dichlorderivate der 16(alpha)-methylpregnanreihe, deren herstellung, deren verwendung als arzneimittel und die sie enthaltenden zusammensetzungen | |
| DE2610497A1 (de) | In 16-stellung disubstituierte 3- ketosteroide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2436234A1 (de) | 3,20-dioxo-16alpha-methyl-pregna1,4,9(11)-triene als arzneimittel, neues verfahren zur herstellung dieser verbindungen und pharmazeutische zusammensetzungen | |
| DE2501091A1 (de) | 17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| DE2535343C2 (de) | 2-(6'-Carboxy-n-hexyl)-3-n-hexyl-cyclopentanole und -derivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2059338C3 (de) | Verwendung von Cyproteronacetat bei der Behandlung der Pubertas praecox | |
| DE1193941B (de) | Verfahren zur Herstellung von therapeutisch wirksamen 16beta-Alkyl-9alpha-fluor-11beta, 17alpha, 21-trioxy-4-pregnen-3, 20-dion-21-acylaten bzw. des entsprechenden 2 | |
| DE1593515C3 (de) | 6-Chlor-21 -fluor-1,2alpha-methylen-DeKa hoch 4,6 -pregnadiene, Verfahren zu deren Herstellung sowie diese enthaltende Mittel | |
| DE2639600A1 (de) | Neue 2,2-dimethylsteroide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| DE2362718A1 (de) | 2,2-dimethylsteroide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| DE1808425C (de) | 3 Oxo 17beta hydroxy 17 alpha (but 2 myl> 13 beta C tief 1 bis C tief 3 alkyl gona 4,9,11 tnene | |
| DE1228257B (de) | Verfahren zur Herstellung von 8-Iso-17alpha-aethinyl-oestradiol sowie von 3-AEthern u3-Estern bzw. 3, 17-Diestern desselben | |
| DE2602331A1 (de) | Derivate des 5-hydroxymethylthiazols und pharmazeutische zusammensetzungen | |
| DE1593509C3 (de) | 1-Hydroxy-7alpha-methyl-östradlol-Derivate, Verfahren zu deren Herstellung sowie diese enthaltende Mittel | |
| DE1468919C (de) | 3,11 Dioxo steroid 4,9 diene und ein Verfahren zu ihrer Herstellung | |
| AT251772B (de) | Verfahren zur Herstellung eines neuen Äthinylderivates des 8-iso-Östrons | |
| DE3028255A1 (de) | Neues halogen-derivat aus der 16 alpha -methylpregnan-reihe, seine herstellung, seine verwendung als arzneimittel und die es enthaltenden zusammensetzungen | |
| DE1793608B1 (de) | 17alpha-Alkyl-,-Alkenyl- oder -Alkinyl-13ss-alkylgon-4-oder-5(10)-en-17ss-ol-3-one | |
| DE1902641C3 (de) | 3-Cyclopentyloxysteroide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1793608C (de) | 17alpha-Alkyl-, -Alkenyl- oder -Alkinyl-13beta-alkylgon-4- oder -5(10)-en-17betaol-3-one. Ausscheidung aus: 1468604 | |
| DE1593465C (de) | 3-(2Chloräthoxy> 17alpha-äthinyl-17 beta-hydroxy-Delta hoch 1,3,5(10)-östratrien und Verfahren zu dessen Herstellung | |
| DE1668857C (de) | 6 alpha, 9 alpha Difluorprednisolon 17 valerat 21 acetat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |